Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
Clinical trial NCT00739063 · TERMINATED
Trial details
- NCT number
- NCT00739063
- Sponsor
- M.D. Anderson Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-07-01
- Primary completion
- 2010-11-01
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.